Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
The biopharmaceutical industry continues to develop mAb (monoclonal antibody)-based biotherapeutics for several applications and disease treatments, progressing from oncology and autoimmune treatments to new medicines for inflammatory and cardiovascular disorders. Nevertheless, the complexity of these molecules creates a significant challenge for analytical technologies to monitor product quality attributes (PQAs) that need to be controlled to guarantee safety and efficacy of the therapeutic product. The CE-ESI-MS platform proved to be a fast and robust tool for therapeutic protein charge variant profiling and facilitated efficient coupling with native mass spectrometry for the generation of highly informative characterisation data.